Literature DB >> 24833135

Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors.

Frédéric Illouz1, Doreen Braun2, Claire Briet2, Ulrich Schweizer2, Patrice Rodien3.   

Abstract

Tyrosine kinase inhibitors (TKIs) are currently used by most oncologists. Among their side effects, thyroid dysfunctions are nowadays clearly observed. Whereas changes in thyroid function tests have been originally described with sunitinib, we now know that many TKIs can induce hypothyroidism and hyperthyroidism. In this study, the various molecules implicated in thyroid dysfunctions are analysed and the latest data on physiopathological mechanisms are approached in order to propose a strategy of thyroid monitoring of patients on TKI therapy.
© 2014 European Society of Endocrinology.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24833135     DOI： 10.1530/EJE-14-0198

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN： 0804-4643            Impact factor:   6.664


  17 in total

1.  New Oral Anti-Cancer Drugs and Medication Safety.

Authors:  Katja Schlichtig; Pauline Dürr; Frank Dörje; Martin F Fromm
Journal:  Dtsch Arztebl Int       Date:  2019-11-15       Impact factor: 5.594

Review 2.  Diverse origins of the myofibroblast—implications for kidney fibrosis.

Authors:  Lucas L Falke; Shima Gholizadeh; Roel Goldschmeding; Robbert J Kok; Tri Q Nguyen
Journal:  Nat Rev Nephrol       Date:  2015-01-13       Impact factor: 28.314

3.  Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM).

Authors:  E Sbardella; A M Isidori; G Arnaldi; M Arosio; C Barone; A Benso; R Berardi; G Capasso; M Caprio; F Ceccato; G Corona; S Della Casa; L De Nicola; M Faustini-Fustini; E Fiaccadori; L Gesualdo; S Gori; A Lania; G Mantovani; P Menè; G Parenti; C Pinto; R Pivonello; P Razzore; G Regolisti; C Scaroni; F Trepiccione; A Lenzi; A Peri
Journal:  J Endocrinol Invest       Date:  2017-11-20       Impact factor: 4.256

Review 4.  2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.

Authors:  Ilaria Muller; Carla Moran; Beatriz Lecumberri; Brigitte Decallonne; Neil Robertson; Joanne Jones; Colin M Dayan
Journal:  Eur Thyroid J       Date:  2019-07-04

Review 5.  New Agents, Emerging Late Effects, and the Development of Precision Survivorship.

Authors:  Eric J Chow; Zoltan Antal; Louis S Constine; Rebecca Gardner; W Hamish Wallace; Brent R Weil; Jennifer M Yeh; Elizabeth Fox
Journal:  J Clin Oncol       Date:  2018-06-06       Impact factor: 44.544

Review 6.  Current and coming challenges in the management of the survivorship population.

Authors:  Eric J Chow; Kirsten K Ness; Gregory T Armstrong; Nickhill Bhakta; Jennifer M Yeh; Smita Bhatia; Wendy Landier; Louis S Constine; Melissa M Hudson; Paul C Nathan
Journal:  Semin Oncol       Date:  2020-03-04       Impact factor: 4.929

Review 7.  Update on the treatment of hypothyroidism.

Authors:  Jacqueline Jonklaas
Journal:  Curr Opin Oncol       Date:  2016-01       Impact factor: 3.645

Review 8.  Endocrinopathies in survivors of childhood neoplasia.

Authors:  Nicole Barnes; Wassim Chemaitilly
Journal:  Front Pediatr       Date:  2014-09-23       Impact factor: 3.418

9.  Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction.

Authors:  Satoshi Koyama; Naritomo Miyake; Kazunori Fujiwara; Tsuyoshi Morisaki; Takahiro Fukuhara; Hiroya Kitano; Hiromi Takeuchi
Journal:  Eur Thyroid J       Date:  2018-02-21

10.  Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer.

Authors:  Alexandra Chrisoulidou; Stylianos Mandanas; Efterpi Margaritidou; Lemonia Mathiopoulou; Maria Boudina; Konstantinos Georgopoulos; Kalliopi Pazaitou-Panayiotou
Journal:  Onco Targets Ther       Date:  2015-09-03       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.